Trials / Withdrawn
WithdrawnNCT04571710
A Trial of SHR1258 in Patients With Biliary Tract Cancer
A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1258 | Drug: SHR1258 400mg |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
- First posted
- 2020-10-01
- Last updated
- 2025-07-24
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04571710. Inclusion in this directory is not an endorsement.